KPTI News and Press, Karyopharm Therapeutics Inc. From 01/17/20

Amedisys (NASDAQ: AMED ) initiated with Outperform rating and $206 (14% upside) price target at Credit Suisse. More news on: Amedisys, Inc., BeiGene, Ltd., Karyopharm Therapeutics Inc., Healthcare stocks news, , Read more ...

The following slide deck was published by Karyopharm Therapeutics Inc. in conjunction with this Read more ...

Karyopharm Therapeutics (NASDAQ: KPTI ) reports 4Q19 XPOVIO net sales in the range of $17M-$18M and $30M-$31M for FY19. More news on: Karyopharm Therapeutics Inc., Healthcare stocks news, Read more ...

-- XPOVIO Unaudited Net Product Sales of between $17 and $18 Million for Fourth Quarter 2019 and between $30 and $31 Million for the Full Year 2019 -- -- Approximately 1,400 XPOVIO Prescriptions Fulfilled in the U.S. from Launch Through Year End 2019 -- NEWTON, Mass., Jan. 13, 2020...

Biotech Pulse The biotech group closed 2019 with its longest rally of the year. It was a welcome change from what had mostly been an uphill battle. While the broader market was sailing from one high to another, biotechs and pharmaceuticals (biopharma) were still marking their 2019 lows in ea...

NEWTON, Mass., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief Executive Officer, will present at the 38th Annual J.P. Morgan Healthcare Conference on Tuesday...

Dosing is underway in a Phase 2 registrational trial in China evaluating I-Mab Biopharma's TJ202/MOR202, a fully human monoclonal antibody targeting a protein found on the surface of cancer cells called CD38, in patients with relapsed/refractory multiple myeloma (MM). The company in-lice...

Nothing provides greater stock price swings in the biotech sector than late-stage clinical trial results and drug approval decisions from the U.S. Food and Drug Administration. A recent research report from investment bank Jefferies (NYSE: JEF)  listed key biotech events for the coming q...

Christmas works like glue, it keeps us all sticking together ." - Rosie Thomas Today, we profile two ' Tier 3 ' names that have been gaining momentum as 2019 comes to a close. Both should see their recently approved products have a significant sales ramp up in 2020 and thus shareholders...

Karyopharm Therapeutics (NASDAQ: KPTI ) has submitted a New Drug Application (NDA) to the FDA seeking accelerated approval for XPOVIO (selinexor), an oral Selective Inhibitor of Nuclear Export (SINE) compound, as a new treatment for patients with relapsed or refractory diffuse large B-Cell...